AVN-211

AVN-211
Clinical data
Other names	CD-008-0173
Identifiers
	IUPAC name 5,7-dimethyl-2-(methylsulfanyl)-3-(phenylsulfonyl)pyrazolo[1,5-a]pyrimidine;
CAS Number	1173103-84-8;
ChemSpider	26387125;
ChEMBL	ChEMBL1668500;
CompTox Dashboard(EPA)	DTXSID001032056;
Chemical and physical data
Formula	C15H15N3O2S2
Molar mass	333.42g·mol−1
3D model (JSmol)	Interactive image;
	SMILES Cc1cc(n2c(n1)c(c(n2)SC)S(=O)(=O)c3ccccc3)C;
	InChI InChI=1S/C15H15N3O2S2/c1-10-9-11(2)18-14(16-10)13(15(17-18)21-3)22(19,20)12-7-5-4-6-8-12/h4-9H,1-3H3; Key:KSAUCBGUWGWPDL-UHFFFAOYSA-N;

AVN-211(CD-008-0173) is adrugwhich acts as a highly selective5-HT₆receptor antagonistand is under development by Avineuro Pharmaceuticals for the treatment ofschizophrenia.^[1]^[2]^[3]In early 2011, it successfully completedphase IIa clinical trials,^[1]^[4]with benefits onpositive symptomsand someprocognitiveeffects observed,^[5]and in mid 2013,phase IIbclinical trials for schizophrenia began.^[6]Avineuro Pharmaceuticals also expressed intention to start clinical trials of AVN-211 forAlzheimer's diseasein 2015.^[6]^[7]^{[needs update]}

References

^^a ^bEllenbroek BA, Cesura AM (13 October 2014)."Antipsychotics and the Dopamine-Serotonin Connection".In Celanire S, Poli S (eds.).Small Molecule Therapeutics for Schizophrenia.Springer. pp. 31, 37.ISBN 978-3-319-11502-3.
^Pharmacology of 5-HT6 receptors.Academic Press. 7 December 2010. pp. 164–.ISBN 978-0-12-384977-9.
^"Drug Development in Schizophrenia: Summary and Table".Pharmaceutical Medicine.28(5): 265–271. 2014.doi:10.1007/s40290-014-0070-6.ISSN 1178-2595.S2CID 8513976.
^"Avineuro Pharmaceuticals, Inc. Reports positive Phase 2a clinical proof of concept trial results on AVN-211, potent small molecule for treatment of schizophrenia".Avineuro Pharmaceuticals, Inc.
^Morozova MA, Lepilkina TA, Rupchev GE, Beniashvily AG, Burminskiy DS, Potanin SS, et al. (August 2014). "Add-on clinical effects of selective antagonist of 5HT6 receptors AVN-211 (CD-008-0173) in patients with schizophrenia stabilized on antipsychotic treatment: pilot study".CNS Spectrums.19(4): 316–323.doi:10.1017/S1092852913000394.PMID 23768250.S2CID 25486838.
^^a ^b"Avineuro Pharmaceuticals, Inc. Announces beginning of Phase 2b clinical studies of AVN-211, potent small molecule for treatment of schizophrenia".Avineuro Pharmaceuticals, Inc.
^Ivachtchenko AV, Lavrovsky Y, Ivanenkov YA (March 2016). "AVN-211, Novel and Highly Selective 5-HT6 Receptor Small Molecule Antagonist, for the Treatment of Alzheimer's Disease".Molecular Pharmaceutics.13(3): 945–963.doi:10.1021/acs.molpharmaceut.5b00830.PMID 26886442.

External links

Pipeline - Avineuro Pharmaceuticals, Inc.

Thisdrugarticle relating to thenervous systemis astub.You can help Wikipedia byexpanding it.

[CelanirePoli2014-1] Ellenbroek BA, Cesura AM (13 October 2014)."Antipsychotics and the Dopamine-Serotonin Connection".In Celanire S, Poli S (eds.).Small Molecule Therapeutics for Schizophrenia.Springer. pp. 31, 37.ISBN 978-3-319-11502-3.

[2] Pharmacology of 5-HT6 receptors.Academic Press. 7 December 2010. pp. 164–.ISBN 978-0-12-384977-9.

[3] "Drug Development in Schizophrenia: Summary and Table".Pharmaceutical Medicine.28(5): 265–271. 2014.doi:10.1007/s40290-014-0070-6.ISSN 1178-2595.S2CID 8513976.

[Avineuro2011-4] "Avineuro Pharmaceuticals, Inc. Reports positive Phase 2a clinical proof of concept trial results on AVN-211, potent small molecule for treatment of schizophrenia".Avineuro Pharmaceuticals, Inc.

[MorozovaLepilkina2013-5] Morozova MA, Lepilkina TA, Rupchev GE, Beniashvily AG, Burminskiy DS, Potanin SS, et al. (August 2014). "Add-on clinical effects of selective antagonist of 5HT6 receptors AVN-211 (CD-008-0173) in patients with schizophrenia stabilized on antipsychotic treatment: pilot study".CNS Spectrums.19(4): 316–323.doi:10.1017/S1092852913000394.PMID 23768250.S2CID 25486838.

[Avineuro2013-6] "Avineuro Pharmaceuticals, Inc. Announces beginning of Phase 2b clinical studies of AVN-211, potent small molecule for treatment of schizophrenia".Avineuro Pharmaceuticals, Inc.

[7] Ivachtchenko AV, Lavrovsky Y, Ivanenkov YA (March 2016). "AVN-211, Novel and Highly Selective 5-HT6 Receptor Small Molecule Antagonist, for the Treatment of Alzheimer's Disease".Molecular Pharmaceutics.13(3): 945–963.doi:10.1021/acs.molpharmaceut.5b00830.PMID 26886442.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

AVN-211

See also

References

External links